Highlights
- •Substantial variability exists in how patients are asked to rate pain intensity.
- •Measures based on patient input may be more valid and meaningful.
- •This study describes the initial development of pain intensity measures.
- •Procedures aligned with US FDA's Clinical Outcome Assessment Qualification Program.
- •Measures will be further evaluated in cognitive interviews and quantitative studies.
Abstract
Perspective
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainReferences
- Development of a PROMIS item bank to measure pain interference.Pain. 2010; 150: 173-182
- Intensity of chronic pain–the wrong metric?.N Engl J Med. 2015; 373: 2098-2099
- Recalled pain ratings: A complex and poorly defined task.J Pain. 2006; 7: 142-149
- Preliminary validation of the Defense and Veterans Pain Rating Scale (DVPRS) in a military population.Pain Med. 2013; 14: 110-123
- Symptoms of major depressive disorder scale: Performance of a novel patient-reported symptom measure.Value Health. 2019; 22: 906-915
- Core outcome measurement instruments for clinical trials in nonspecific low back pain.Pain. 2018; 159: 481-495
- A proposed set of metrics for standardized outcome reporting in the management of low back pain.Acta Orthop. 2015; 86: 523-533
- Simple pain rating scales hide complex idiosyncratic meanings.Pain. 2000; 85: 457-463
- Immpact. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.Pain. 2005; 113: 9-19
European Medicines Agency: Qualification of Novel Methodologies for Drug Development: Guidance to Applicants, Amsterdam, The Netherlands, 2020
- Individual differences in pain: understanding the mosaic that makes pain personal.Pain. 2017; 158: S11-S18
- Imagined examples of painful experiences provided by chronic low back pain patients and attributed a pain numerical rating score.Front Neurosci. 2019; 13: 1331
- Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review.J Pain Symptom Manage. 2011; 41: 1073-1093
- Self-report scales and procedures for assessing pain in adults.in: Turk D.C. Melzack R. Handbook of pain assessment. The Guilford Press, New York2011: 19-44 (Eds.)
- Qualitative development and content validity of the non-small cell lung cancer symptom assessment questionnaire (NSCLC-SAQ), a patient-reported outcome instrument.Clin Ther. 2016; 38: 794-810
- The magical number 7, plus or minus 2 - some limits on our capacity for processing information.Psychol Rev. 1956; 63: 81-97
- Clinical outcome assessment in clinical trials of chronic pain treatments.Pain Rep. 2021; 6: e784
- Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1–eliciting concepts for a new PRO instrument.Value Health. 2011; 14: 967-977
- Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 2–assessing respondent understanding.Value Health. 2011; 14: 978-988
- Optimal number of response categories in rating scales: Reliability, validity, discriminating power, and respondent preferences.Acta Psychol (Amst). 2000; 104: 1-15
- Barriers to chronic pain measurement: A qualitative study of patient perspectives.Pain Med. 2015; 16: 1256-1264
- Pain intensity rating training: Results from an exploratory study of the ACTTION PROTECCT system.Pain. 2016; 157: 1056-1064
- Quality of pain intensity assessment reporting: ACTTION systematic review and recommendations.J Pain. 2015; 16: 299-305
- Development and preliminary validation of the focused analgesia selection test to identify accurate pain reporters.J Pain Res. 2017; 10: 319-326
- Accurate pain reporting training diminishes the placebo response: Results from a randomized, double-blind, crossover trial.PLoS One. 2018; 13e0197844
U.S. Food & Drug Administration: Patient-Focused Drug Development Guidance Public Workshop: Methods to Identify What is Important to Patients and Select, Develop or Modify Fit-for-Purpose Clinical Outcome Assessments, Center for Drug Evaluation and Research, Silver Spring, MD, 2018
U.S. Food & Drug Administration: Patient-Focused Drug Development Guidance Public Workshop: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making, Center for Drug Evaluation and Research, Silver Spring, MD, 2019
U.S. Food & Drug Administration: Patient-Focused Drug Development: Collecting Comprehensive and Representative Input, Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research, 2020
U.S. Food & Drug Administration: Patient Focused Drug Development: Collecting Comprehensive and Representative Input: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders, Center for Drug Evaluation and Research, Silver Spring, MD, 2020
U.S. Food & Drug Administration: Qualification Process for Drug Development Tools: Guidance for Industry and FDA Staff, Center for Drug Evaluation and Research, Silver Spring, MD, 2020
U.S. Food & Drug Administration: Patient-Focused Drug Development: Methods to Identify What Is Important to Patients Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders, Center for Drug Evaluation and Research, Silver Spring, MD, 2022
Article info
Publication history
Footnotes
Financial support for this article was provided by the ACTTION public-private partnership with the FDA, which has received research contracts, grants, or other revenue from the FDA, multiple pharmaceutical and device companies, philanthropy, and other sources. No official endorsement by the FDA or the pharmaceutical and device companies that have provided unrestricted grants to support the activities of ACTTION should be inferred. The views expressed in this article are those of the authors, none of whom have conflicts of interest related to the specific issues discussed in this article.
